Least Burdensome Additional-Info Requests? US FDA Needs Metrics, GAO Says
Executive Summary
The US Government Accountability Office says FDA needs more information to prove that is properly applying least-burdensome concepts for deficiency or additional-information letters sent to companies while reviewing pre-market submissions. FDA defends its performance, but plans to conduct more assessments.
You may also be interested in...
Early Signs Positive From FDA's Least-Burdensome Training
An initial evaluation of US FDA's congressionally mandated staff training programs on "least burdensome" processes are promising, the agency says, but more time is needed to track data on more tangible positive impacts for device companies. Industry, meanwhile, will likely need more convincing.
'Least Burdensome' Supersized? Draft Guidance Outlines An Expanded View Of The US FDA Concept
The US agency issued a draft guidance that brings the 20-year old concept of "least burdensome" in medical device regulation to all corners of the device center's activities.
Vanda Comes Up Empty Handed As US Supreme Court Denies Hetlioz Appeal
Vanda looks likely to have to face up to unimpeded US generic competition to its core Hetlioz brand, after a further denial in its litigation against ANDA sponsors Teva and Apotex.